KANTAR HEALTH BLOG

kh_blog_hero_1600px
  • Opdivo Making Strides in Advanced Hepatocellular Carcinoma

    by Stephanie Hawthorne  |  Jan 23, 2017
    Oncology Conference Insight: ASCO GI 2017 --- It is an exciting time for patients and their doctors fighting advanced hepatocellular carcinoma (HCC). In mid-2016 the HCC community witnessed the first randomized trial to successfully improve survival outcomes in Nexavar® (sorafenib, Onyx/Amgen/Bayer)-pretreated HCC when the multikinase inhibitor Stivarga® (regorafenib, Bayer) demonstrated a 38% reduction in the risk of death compared with placebo in the Phase III RESOURCE trial.
  • Opdivo Shows Appetite for Gastric Cancer

    by Jay Grisolano  |  Jan 20, 2017
    Oncology Conference Insight: ASCO GI 2017 --- Before Cyramza® (ramucirumab, Eli Lilly and Co) was approved by the FDA in 2014, there were no targeted therapy regimens approved for use in relapsed/refractory gastric cancer. Cyramza’s approval as a monotherapy or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing systemic therapy was based on the positive results of two Phase III studies in relapsed gastric patients.
  • The Patient as a Person

    by Tom Haskell  |  Dec 13, 2016
    Instead of understanding “the patient,” pharma will need to see “the person who happens to be living with a disease.”
  • Oncology Conference Insight: ASH 2016 --- Immunotherapies such as checkpoint inhibitors have had a dramatic impact on treatment paradigms for many tumor types over the past few years, and their full potential is far from being realized. Hot on the heels of checkpoint inhibitors are engineered, adoptive T-cell therapies that represent another promising advancement.
  • GALLIUM turns Gazyva into gold in NHL

    by Jay Grisolano  |  Dec 5, 2016
    Oncology Conference Insight: ASH 2016 --- In the management of non-Hodgkin lymphoma (NHL), Rituxan-based therapy forms the foundation for therapy in all settings. This holds true for most subtypes of NHL, including follicular lymphoma, mantle cell lymphoma, and diffuse B-cell lymphoma. While Rituxan-based therapy is highly effective and leads to improvement in survival rates, patients are rarely cured, and relapse is common, occurring in about 20-30% of patients.
More than one Google Analytics scripts are registered. Please verify your pages and templates.